



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
 (Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**  
**FOR THE PERIOD ENDED 30 SEPT 2011**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 9/30/2011 RM'000	CURRENT YEAR QUARTER 9/30/2010 RM'000	CURRENT YEAR TO DATE 9/30/2011 RM'000	CURRENT YEAR TO DATE 9/30/2010 RM'000
Revenue	36,767	34,464	105,096	99,242
Cost of Sales	(19,802)	(18,184)	(59,030)	(55,821)
<b>Gross Profit</b>	<b>16,965</b>	<b>16,280</b>	<b>46,066</b>	<b>43,421</b>
Other operating income	94	103	501	504
Distribution costs	(3,102)	(3,176)	(8,227)	(8,665)
Administration expenses	(3,349)	(2,405)	(9,434)	(6,737)
Other operating expenses	(771)	(571)	(1,882)	(1,689)
<b>Profit from operations</b>	<b>9,837</b>	<b>10,231</b>	<b>27,024</b>	<b>26,834</b>
Finance costs	(111)	(10)	(132)	(32)
<b>Profit before taxation</b>	<b>9,726</b>	<b>10,221</b>	<b>26,892</b>	<b>26,802</b>
Taxation	(2,205)	(2,602)	(6,515)	(6,747)
<b>Profit after tax for the period</b>	<b>7,521</b>	<b>7,619</b>	<b>20,377</b>	<b>20,055</b>
<b>Other comprehensive income</b>	-	-	-	-
<b>Total other comprehensive income for the period</b>	<b>7,521</b>	<b>7,619</b>	<b>20,377</b>	<b>20,055</b>
<b>Profit attributable to:</b>				
Shareholders of the Company	7,521	7,619	20,377	20,055
Minority interest	-	-	-	-
	<b>7,521</b>	<b>7,619</b>	<b>20,377</b>	<b>20,055</b>
<b>Total other comprehensive income attributable to:</b>				
Shareholders of the Company	7,521	7,619	20,377	20,055
Minority interest	-	-	-	-
	<b>7,521</b>	<b>7,619</b>	<b>20,377</b>	<b>20,055</b>
Earnings per share (sen)				
Basic (based on weighted average)	5.42	5.49	14.68	14.45
Diluted (based on weighted average)	5.42	5.49	14.68	14.45

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
 (Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 30 SEPT 2011**

	AS AT END OF CURRENT PERIOD 30/9/2011 RM'000	AS AT PRECEDING FINANCIAL YEAR ENDED 31/12/2010 RM'000
<b>ASSETS</b>		
Property, Plant and Equipment	101,353	100,249
<b>Total non-current assets</b>	<b>101,353</b>	<b>100,249</b>
Inventories	40,400	34,003
Trade & Other Receivables	43,313	34,804
Related Company	1,499	951
Assets classified as held for sale	1,740	1,740
Current tax assets	451	-
Cash & Cash Equivalents	8,124	24,732
<b>Total current assets</b>	<b>95,527</b>	<b>96,230</b>
<b>Total Assets</b>	<b>196,880</b>	<b>196,479</b>
<b>EQUITY</b>		
Share Capital	69,739	69,739
Reserves	94,815	89,708
Treasury Shares	(1,578)	(1,578)
<b>Total Equity</b>	<b>162,976</b>	<b>157,869</b>
<b>LIABILITIES</b>		
Deferred Tax Liability	4,470	3,821
Long Term Borrowings	4,165	10,416
<b>Total non-current liabilities</b>	<b>8,635</b>	<b>14,237</b>
Trade & Other Payables	15,309	13,509
Amount due to related company	776	1,324
Provision	850	850
Taxation	-	356
Term Loan	8,334	8,334
<b>Total current liabilities</b>	<b>25,269</b>	<b>24,373</b>
<b>Total Liabilities</b>	<b>33,904</b>	<b>38,610</b>
<b>Total Equity &amp; Liabilities</b>	<b>196,880</b>	<b>196,479</b>
<b>Net assets per share (RM)</b>	<b>1.17</b>	<b>1.13</b>

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT**  
**FOR THE PERIOD ENDED 30 SEPT 2011**

	30 Sept 11 RM '000	30 Sept 10 RM '000
Cash generated from operations:	16,427	32,898
Income taxes paid	(6,673)	(5,207)
<b>Net cash generated from operating activities</b>	<b>9,754</b>	<b>27,691</b>
<b>Net cash used in investing activities</b>	<b>(4,841)</b>	<b>(20,911)</b>
<b>Cash generated from financing activities</b>		
Dividend paid	(15,270)	(14,229)
Drawdown of term loan	-	9,574
Repayment of term loan	(6,251)	(4,167)
<b>Net cash used in financing activities</b>	<b>(21,521)</b>	<b>(8,822)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(16,608)</b>	<b>(2,042)</b>
Cash and cash equivalents as at 1 January	24,732	26,999
<b>Cash and cash equivalents as at 30 Sept (I)</b>	<b>8,124</b>	<b>24,957</b>

(I) Cash and cash equivalents comprise:

	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	3,867	7,440
Fixed deposits placed with licensed financial institutions	4,257	17,517
	<b>8,124</b>	<b>24,957</b>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)